Pfizer Inc (PFE.N) said it expected 2021 sales of the COVID-19 vaccine it developed with German partner BioNTech SE to reach $36 billion and forecast another $29 billion from the shot in 2022, topping analyst estimates for both years.
The U.S. drugmaker said it is seeking to sign more vaccine deals with countries, which could drive sales even higher next year. It has the capacity to produce 4 billion doses in 2022 and has based its projections on sales of 1.7 billion doses.
Confirmed Omicron cases, deaths, and admissions
France, Israel, Denmark, and Ireland have the highest cases per capita of Omicron in the world. This shows what happens with massive surges of virus spread, even ones with 60-70% less severity.
Source: Dr. Eric Topol, Scripps Institute